Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Other Non Operating Income (2021 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Non Operating Income for 5 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 61.27% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.3 million through Dec 2025, up 85.64% year-over-year, with the annual reading at $28.3 million for FY2025, 85.64% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $2.9 million at Intellia Therapeutics, down from $10.2 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $10.2 million in Q3 2025, with the low at -$7.9 million in Q2 2024.
  • Average Other Non Operating Income over 5 years is $3.1 million, with a median of $4.7 million recorded in 2025.
  • The sharpest move saw Other Non Operating Income crashed 2306.02% in 2022, then skyrocketed 464.03% in 2023.
  • Over 5 years, Other Non Operating Income stood at -$822000.0 in 2021, then plummeted by 303.89% to -$3.3 million in 2022, then skyrocketed by 332.86% to $7.7 million in 2023, then fell by 2.35% to $7.5 million in 2024, then crashed by 61.27% to $2.9 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $2.9 million, $10.2 million, and $8.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.